Table 2.
HR repair proteins targeted in cancer therapy.
| HR | |||||
|---|---|---|---|---|---|
| Protein | Drug Name | Combined Treatment | Possible Synthetic Lethal Interaction | Clinical Trial | References |
| MRE11 | Mirin | PARP1 inhibition | [126,127,128] | ||
| RAD51 | B02 | Ionizing radiation Topoisomerases I and II inhibitors |
PARP1 inhibition | [129,130,131,132] | |
| RI-1 | Cisplatin Ionizing radiation |
[132,133] | |||
| IBR120 | Ionizing radiation | [134,135] | |||
| CYT-0851 | NCT03997968 | [125] | |||
| BRCA1 | PARP1 inhibition | [24,137,138] | |||
| BRCA2 | |||||
| RAD52 | F79 6-OH-dopa D-I03 |
Cisplatin | PARP1 inhibition BRCA2 inhibition BRCA1/PALB2 inhibition |
[139,140,141,142] | |
| A5MP AICAR/ZMP |
BRCA1 inhibition | ||||
| NP-004255 F779-0434 |
BRCA2 inhibition | ||||
For each target it is reported: name of the drug currently in analysis; combination of target inhibition and classic anti-cancer therapy under study; possible synthetic lethality interaction; ongoing clinical trials with the drug; references.